Magadh Chronicle

DelveInsight Business Research LLP

DelveInsight’s “Non-Alcoholic Fatty Liver Disease (NAFLD) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Non-Alcoholic Fatty Liver Disease (NAFLD), historical and forecasted epidemiology as well as the Non-Alcoholic Fatty Liver Disease (NAFLD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the Key Facts of the Non-Alcoholic Fatty Liver Disease Market Report:

• Based on the study conducted by Ratziu et al. (2010), the prevalence of NAFLD in the general population assessed by ultrasonography is 20–30% in Europe and 34% in US adults. The prevalence of NAFLD increases with age, is highest in males between 40 and 65 years. In retrospective series from tertiary referral centers, bridging fibrosis is seen in 25–33% of NASH patients at diagnosis, including cirrhosis in 10–15%.

Key Benefits of the Non-Alcoholic Fatty Liver Disease Market Report:

• The report covers the descriptive overview of Non-Alcholic Fatty Liver Disease

• Disorder, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Non Alcoholic Fatty Liver DiseaseDisorder epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Post-Transplant Lymphoproliferative Disorder is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of the Post-Transplant Lymphoproliferative Disorder market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Post-Transplant Lymphoproliferative Disorder market

Got queries? Click here to know more about the Non Alcoholic Fatty Liver Disease Market Landscape

Non-Alcoholic Fatty Liver Disease Overview

Non-alcoholic Fatty Liver Disease (NAFLD) is a very common disorder and refers to a group of conditions where there is an accumulation of excess fat in the liver of people who drink little or no alcohol. The most common form of NAFLD is a nonserious condition called fatty liver. In fatty liver, fat accumulates in the liver cells. Although having fat in the liver is not normal, by itself it probably does not damage the liver. A small group of people with NAFLD may have a more serious condition named non-alcoholic steatohepatitis (NASH). In NASH, fat accumulation is associated with liver cell inflammation and different degrees of scarring. NASH is a potentially serious condition that may lead to severe liver scarring and cirrhosis. Cirrhosis occurs when the liver sustains substantial damage, and the liver cells are gradually replaced by scar tissue, which results in the inability of the liver to work properly. Some patients who develop cirrhosis may eventually require a liver transplant (surgery to remove the damaged liver and replace it with a “new” liver). The majority of individuals with NAFLD have no symptoms and a normal examination. Children may exhibit symptoms such as abdominal pain, which may be in the center or the right upper part of the abdomen, and sometimes fatigue. However, other causes of abdominal pain and fatigue should be considered. On physical examination, the liver might be slightly enlarged and some children may have patchy, dark discoloration of the skin present (acanthosis nigricans) most commonly over the neck and the underarm area.

Non-Alcoholic Fatty Liver Disease Epidemiological Insights:

• According to the study conducted by Caballería et al. (2010), titled, “Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain,” 766 individuals with a mean age of 53+/-14 years (range 17-83, 42.2% men) were included in the study. 198 individuals presented NAFLD with echographic criteria (prevalence 25.8, 33.4% men and 20.3% women P<0.001). 

• According to the study conducted by Hamaguchi et al. (2012), the prevalence of NAFLD in women increases with age, but does not alter with age in men. Furthermore, the prevalence of NAFLD in premenopausal women (6%) was lower than that in men (24%) and in postmenopausal women (15%). The associations of the postmenopausal state and hormone replacement therapy with NAFLD were statistically significant in a univariate logistic regression model. At the follow-up examination, 67 women (5%) were newly diagnosed with NAFLD. 

Non-Alcoholic Fatty Liver Disease Epidemiological Segmentation 

• Non-Alcoholic Fatty Liver Disease prevalent cases 

• Non-Alcoholic Fatty Liver Disease incident cases 

• Non-Alcoholic Fatty Liver Disease diagnosed cases 

• Non-Alcoholic Fatty Liver Disease treatment cases 

Non-Alcoholic Fatty Liver Disease Market Outlook 

The Non Alcoholic Fatty Liver Disease market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted Non Alcoholic Fatty Liver Disease market trends by analyzing the impact of current Post-Transplant Lymphoproliferative Disorder therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

This segment gives a thorough detail of the Non-Alcoholic Fatty Liver Diseasemarket trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Non Alcoholic Fatty Liver Diseasemarket data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Post-Transplant Lymphoproliferative Disorder market in 7MM is expected to witness a major change in the study period 2019-2032.

Learn more by requesting for sample @ Non-Alcoholic Fatty Liver Disease  Market  Landscape

Non-Alcoholic Fatty Liver Disease Key Companies

• Scandio BioTherapeutics 

• Madrigal Therapeutics 

• Roche 

• Merck 

• Zydus Therapeutics 

• And many others 

Non-Alcoholic Fatty Liver Disease  Therapies 

• SAMe 

• Sorbitol

• Resmetirom

• ALT-801

• CB4211 D

Table of Contents

1.  Key Insights 

2.  Non-Alcoholic Fatty Liver Disease  Report Introduction 

3.  Executive Summary of the Non-Alcoholic Fatty Liver Disease  Market  

4.  Non-Alcoholic Fatty Liver Disease  Disease Background and Overview

5.  Non-Alcoholic Fatty Liver Disease  Epidemiology and patient population

6.  The United States 

7.  EU 5

8.  Non-Alcoholic Fatty Liver Disease  Market Emerging Therapies

9.  Non-Alcoholic Fatty Liver Disease  Market Drivers 

10.  Non-Alcoholic Fatty Liver Disease  Market Barriers 

11.  Market Access and Reimbursement of Therapies

12.  Appendix

13.  Non-Alcoholic Fatty Liver Disease  Market Report Methodology

14.  DelveInsight Capabilities

15.  Disclaimer

16.  About DelveInsight

Click here to read more about Non-Alcoholic Fatty Liver Disease  Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services